Second Time's the Charm: Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55)
研究概览
简要总结
The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.
详细描述
Studies have shown prevention of cardiovascular adverse events is directly proportional to percent reduction in low-density lipoprotein (LDL). This evidence explains why LDL targets for secondary prevention have continued to be lowered. Cholesterol guidelines have been updated recently and encourage the use of multiple lipid lowering therapies, in addition to statins, for secondary prevention. However, these novel agents can be expensive and difficult to acquire, making prescribing challenging for providers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of coronary artery disease
- •low-density lipoprotein (LDL) > 55
- •Primary Care Physician at 1 of 6 identified clinics
排除标准
- •Patients who are no longer an active patient of one of the internal medicine practices
- •Patients whose cholesterol is managed by another practice
- •Women of childbearing age/potential
- •Patients residing in hospice/Long Term Care facilities
- •End-stage liver disease
研究组 & 干预措施
Pharmacist Intervention
Pharmacist review of patient chart and follow up visits to prescribe appropriate therapy for hyperlipidemia.
干预措施: Pharmacist Intervention in lipid therapy (Other)
Control
Chart review only
结局指标
主要结局
Number of Subjects Who Meet Low-density Lipoprotein (LDL) at Goal (<55)
时间窗: Month 5
patients with LDL within goal (\<55) (yes/no)
次要结局
- Percent Change in Low-density Lipoprotein (LDL)(Baseline to end of study period up to Month 5)
- Number of Participants With Medications Initiated or Titrated(Baseline to end of study period up to Month 5)
- Prevalence of Elevated Lipoprotein(a)(Baseline to end of study period up to Month 5)